INTRODUCTION
Cytarabine plays an important role in the treatment of patients with acute myeloid leukemia (AML). Administration at a daily dose of 100 to 200 mg/m 2 for 7 to 10 days in combination with 3 days of an anthracycline is the most commonly used remission induction regimen. This schedule results in complete remission (CR) rates of 60% to 80% depending on age and cytogenetic and molecular features of the acute leukemia. 1, 2 Higher doses of cytarabine (2,000 to 6,000 mg/m 2 per day for eight to twelve doses) for induction of remission and/or in consolidation have been tested in various AML trials.
3-17 Thus far, four randomized trials have been reported that evaluated increased dosages of cytarabine as part of the induction regimen of previously untreated patients. 14-17 Despite these experiences, definite conclusions on the value of high-dose (HD) cytarabine remain hard to draw. Possible reasons are insufficient numbers of patients per trial or more intensive induction strategies in the control arm. 13 On the basis of the encouraging results of the Australian Leukemia Study Group reported by Bishop et al, 14 the Leukemia Groups of the European Organisation for Research and Treatment of Cancer (EORTC) and the Gruppo Italiano Malattie Ematologiche dell' Adulto (GIMEMA) conducted a large randomized trial (AML-12; Combination Chemotherapy, Stem Cell Transplant and Interleukin-2 in Treating Patients With Acute Myeloid Leukemia) to compare HD cytarabine versus standard-dose (SD) cytarabine in the induction regimen. In both arms, patients who achieved CR after one or two induction courses received a single consolidation course containing intermediate-dose cytarabine and allogeneic or autologous stem-cell transplantation (SCT).
PATIENTS AND METHODS

Eligibility
Untreated patients with de novo or secondary AML age 15 to 60 years were eligible. Main inclusion criteria were morphologically confirmed AML with bone marrow containing 30% or more blasts; a WHO performance status of 3 or less; no evidence of severe concurrent cardiac, pulmonary, neurologic, or metabolic disorders or uncontrolled infections; and adequate liver and renal function tests. Secondary AML was defined as AML following hematologic or nonhematologic malignancies or after exposure to chemotherapy or radiation. Patients with promyelocytic leukemia, AML after myelodysplastic syndrome of more than 6 months duration, or AML/blast crisis after chronic myeloproliferative disease or during concomitant other progressive malignant disease were excluded (Fig 1) .
The study was approved by the internal review boards of EORTC and GIMEMA and the ethical committee of each participating institution and was conducted in accordance with the Declaration of Helsinki. All patients signed the informed consent form.
Study Design
The study aimed to compare efficacy and toxicity of an induction regimen that contained HD cytarabine versus SD cytarabine. Primary end point was overall survival (OS). Secondary end points were CR rate, disease-free survival (DFS), toxicity, and rate of autologous or allogeneic SCT in each arm. Patients who fulfilled the eligibility criteria were randomly assigned to the standard or experimental arm at the EORTC Headquarters in Brussels, Belgium. At random assignment, patients were stratified according to center, age (15 to 45 years v 46 to 60 years), WHO performance status (grade 0 to 1 v grade 2 v grade 3), and total leukocyte count (Ͻ 25 v 25 to 99.9 v Ն 100 ϫ 10 9 /L) by using a minimization technique (Fig 2) .
The basis for our standard remission induction regimen was the standard arm of the EORTC-GIMEMA Study AML-10 (Daunorubicin Versus Mitoxantrone Versus Idarubicin As Induction and Consolidation Chemotherapy for Adults With Acute Myeloid Leukemia: The EORTC and GIMEMA Groups Study AML-10), 2 which included daunorubicin, etoposide, and 10 days of cytarabine. At that time, the standard arm in the AML-10 trial showed the lowest toxicity with equal efficacy compared with the experimental arms. Furthermore, this schedule had important similarities with the standard arm of the Australian trial.
14 In the experimental arm, 4 days of HD cytarabine replaced the 10 days of SD cytarabine similar to the experimental arm of the Australian trial. Thus, remission induction consisted of daunorubicin (50 mg/m 2 per day as a 5-minute intravenous [IV] infusion on days 1, 3, and 5) and etoposide (50 mg/m 2 per day by 1-hour IV infusion on days 1 through 5) in both arms, in combination with either 10 days of cytarabine (100 mg/m 2 per day as continuous IV infusion) in the standard arm (SD cytarabine) or cytarabine (3,000 mg/m 2 every 12 hours as a 3-hour IV infusion on days 1, 3, 5, and 7) in the experimental arm (HD cytarabine). Assessment of response was planned by day 31 of induction. Criteria for response and relapse followed the Report of the National Cancer Institute-Sponsored Workshop. 18 In case of partial remission, a second identical induction course was given. Once CR with or without full hematologic recovery was achieved, a single consolidation course identical with the consolidation course of EORTC-GIMEMA AML-10, 2 consisting of intermediate-dose cytarabine (500 mg/m 2 every 12 hours as a 2-hour IV infusion on days 1 through 6) plus daunorubicin (50 mg/m 2 per day as a 5-minute infusion on days 4 through 6) was administered. In some centers, allogeneic SCT (allo-SCT) was strongly recommended after consolidation for patients younger than age 50 years or up to age 60 years with an HLA-compatible family donor, or for patients without a family donor who had AML with chromosome abnormalities involving 3q, 5, t(6;9), t(9;22), 7, or 11q23 complex abnormalities, or for those with a matched unrelated donor who needed a second remission induction course. All patients not eligible for allo-SCT were planned for autologous SCT. Mobilization and collection of autologous stem cells of those patients was scheduled during the recovery phase of consolidation. Lenograstim (150 g/m 2 per day) was given by daily subcutaneous injections from day 20 of consolidation until completion of the blood stem-cell harvest. All CR patients without a suitable stem-cell donor were eligible for a second random assignment involving 5 days of low-dose subcutaneous interleukin-2 as monthly courses for a year or until relapse. Results of the second random assignment are not within the scope of this report.
End Points
OS was defined as the time interval from random assignment until death, whatever the cause. Follow-up of patients still alive was censored at the moment of last visit or contact. DFS was defined as the time from CR until the first relapse or death as a result of any cause. For patients still alive in first CR, DFS was censored on the date of last visit or contact. Because allo-SCT was integrated into the treatment scheme, follow-up of patients was not censored at the date of allo-SCT. Event-free survival (EFS) for patients in CR was defined as DFS, whereas for patients who did not reach CR, EFS was set as being an event at time zero. The duration of hematologic recovery was defined as the time from the first day of the chemotherapy course until neutrophil level was more than 0.5 ϫ 10 9 /L or platelet level was more than 10 ϫ 10 9 /L or more than 100 ϫ 10 9 /L; patients without recovery were censored at day 99. Toxicity was evaluated according to Common Toxicity Criteria version 2.0.
Statistical Analysis
The study was powered to detect an 8% treatment difference (from 35% to 43%) in the 5-year OS rate, corresponding to a hazard ratio (HR) of 0.80 (two-sided ␣, 5%; power, 95%) and a treatment-age (15 to 45 v 46 to 60 years) interaction with an 80% power. A total of 2,000 randomly assigned patients was required to follow 1,100 of them until death.
Time-to-event outcomes were computed by using the Kaplan-Meier technique and were compared by using the two-tailed log-rank test.
19 Cumulative incidence of relapse and of the incidence of death in CR were estimated by using competing risk methods. 19 Forest plot technique was used to obtain treatment HR estimate, along with its 95% or 99% CI, and to perform subgroup analyses. The Cox proportional hazards model stratified by cytogenetic-molecular features was used to adjust the treatment comparison by initial patient-disease features. Fisher's exact test and linear logistic regression model were used to compare the CR rates after induction.
All efficacy analyses were performed according to the intention-to-treat principle (all patients randomly assigned were included, except for all patients [n ϭ 63] from three centers with extremely poor data reporting). To avoid selection bias, analysis of the impact of allo-SCT on the outcome was performed according to the availability of a donor, and treatment comparison regarding DFS was performed separately in patients with and without a donor. Data for patients who started the protocol treatment were used for response rate, EFS, and adverse event comparison, and data for patients who reached CR were used for DFS and time-to-recovery comparisons. SAS 9.3 software (SAS Institute, Cary, NC) was used for the statistical analyses.
RESULTS
Patients
Between September 1999 and January 2008, 1,942 patients were randomly assigned: 872 from 22 EORTC and 1,070 from 42 GIMEMA 2 every 12 hours as a 2-hour IV infusion on days 1 through 6) plus daunorubicin (50 mg/m 2 per day as a 5-minute infusion on days 4 through 6). Allo-SCT, allogeneic stem-cell transplantation; auto-PBSCT, autologous peripheral blood SCT; IL-2, interleukin-2 (4 ϫ 10 6 IU/m 2 subcutaneous injection on day 1 ϩ 8 ϫ 10 6 IU/mcenters. Their median age was 45 years (range, 15 to 60 years). As induction, 969 patients were randomly assigned to receive the SD cytarabine and 973 to receive the HD cytarabine regimen. The two treatment arms were matched with respect to baseline characteristics (Table 1) . Fifty-three randomly assigned patients were ineligible-25 (2.6%) in the SD cytarabine and 28 (2.9%) in the HD cytarabine arm-but they were included in the main intention-to-treat analysis.
Reasons for ineligibility were wrong diagnosis (acute lymphoblastic leukemia, chronic myeloblastic leukemia, acute promyelocytic leukemia, or myelodysplastic syndrome in 40 patients and other reasons in 13 patients.
Treatment Phases and Outcomes
A total of 1,900 patients started induction treatment: 951 in the SD cytarabine and 949 in the HD cytarabine arm (Fig 1) . Reasons for not starting induction were refusal (n ϭ 4), death before treatment (n ϭ 10), ineligibility (n ϭ 21), and other (n ϭ 7). Details regarding treatment phases and outcomes in both randomly assigned arms are shown in Table 2 . A significantly higher percentage of patients receiving HD cytarabine achieved CR (P ϭ .009). The death rate after one or two induction courses was similar in both arms. Among 1,432 patients who achieved CR, consolidation course was administered to 1,337 patients: 93.7% in the SD cytarabine arm and 93.0% in the HD cytarabine arm. Reasons for not receiving consolidation were death before treatment (n ϭ 7), no longer in CR (n ϭ 14), persisting infection (n ϭ 34), persisting organ failure (n ϭ 7), neurologic toxicity (n ϭ 7), and other (n ϭ 26).
At a median follow-up of 6 years, 1,091 patients had died: 568 (59.7%) in the SD cytarabine arm and 523 (55.2%) in the HD cytarabine arm. The OS rate at 6 years was 40.6% for all patients: 38.7% in the SD cytarabine arm and 42.5% in the HD cytarabine arm (HR, 0.89; P ϭ .06). Comparison of treatment outcome stratified for cytogenetic features and adjusted for several other risk factors was significant in favor of HD cytarabine (HR, 0.86; P ϭ .009; Fig 3A) .
Subgroup Analysis
Planned subgroup analyses according to age group were performed for different end points (Tables 2 and 3 , Fig 3B and Fig 4) . Both Abbreviations: AML, acute myeloid leukemia; CR, complete remission; HD, high dose; ITD, internal tandem duplication; SD, standard dose.
‫ء‬
Good risk includes the abnormalities inv(16) and t(8;21). Intermediate risk includes normal karyotypes and those with ϪY only, without FLT3-ITD mutation. Very bad risk/FLT3-ITD includes presence of Ϫ5/5qϪ and Ϫ7/7qϪ, complex abnormalities, 3q, t(6;9), t(9;22), and 11q23, and all patients with an FLT3-ITD mutation. Other abnormalities were pooled into a separate "bad risk" cytogenetic risk group. Patients with unknown, not done, or unsuccessful cytogenetic tests were grouped together as "unknown risk." age (P ϭ .06) and disease type (de novo v secondary AML P ϭ .05) had an impact on treatment comparison regarding survival (Fig 4) . For patients age 15 to 45 years, HD cytarabine significantly improved the CR rate (82.4% v 75.6%; P ϭ .01), the 6-year EFS rate (43.6% v 35.1%; P ϭ .003), and the 6-year OS rate (51.9% v 43.3%; P ϭ .009); in older patients, only the CR rate was higher in the HD cytarabine arm. In the younger age group, HD cytarabine increased the 6-year DFS rate compared with SD cytarabine (52.8% v 46.4%; P ϭ .07) by decreasing the relapse incidence by 5% (40.3% v 45.3%) and without increasing the incidence of death in CR (Table 2 ). In contrast, in the older age group, the decrease of 5.1% (46.0% v 51.1%) in relapse incidence was counterbalanced by an increase of 4.6% (18.5% v 13.1%) in the incidence of death in CR (Table 2) . Furthermore, in the younger age group, HD cytarabine improved OS more in patients with secondary AML (HR, 0.23; P ϭ .005) than in patients with de novo AML (HR, 0.83; P ϭ .04).
Interestingly, improvement of the CR rate in patients with secondary AML was detected both in younger (odds ratio, 5.99) and in older patients (odds ratio, 3.75), as was the OS in patients with very-bad-risk cytogenetic abnormalities and/or FLT3-ITD (internal tandem duplication) mutation both in younger (HR, 0.70; P ϭ .02) and older patients (HR, 0.80, P ϭ .14). These findings were confirmed by multivariable analyses (Table 3) , and also when eligible patients who started the allocated treatment were considered (data not shown).
DFS According to Donor Availability and Age Group
In the younger age group, availability of a family donor did improve the outcome in both randomly assigned arms. In the SD cytarabine arm, the 6-year DFS rate was 57.4% for patients with a donor and 39.5% for patients without a donor; in the HD cytarabine arm, the 6-year DFS rates were 62.6% and 46.4%, respectively. The estimated treatment HR was 0.84 in patients with a donor and 0.83 in patients without a donor.
For the older age group, the 6-year DFS was approximately 35% in patients with or without a family donor, whether they received HD or SD cytarabine. The estimated treatment HR was close to 1 in each group. Adding patients with unrelated donors to the group of patients with related donors did not significantly alter the treatment comparisons (data not shown).
Adverse Events
Grade 3 and 4 nonhematologic toxicities of the induction courses were not different in the two randomly assigned arms except for conjunctivitis grade 2 to 3 toxicity, which occurred more frequently in the HD cytarabine arm than in the SD cytarabine arm (12.4% v 0.5%). Grade 3 and 4 infectious complications were reported in 67.6% of patients receiving SD cytarabine and in 66.2% of those receiving HD cytarabine. In the two age groups (15 to 45 and 46 to 60 years), adverse event profiles in the two randomly assigned arms were remarkably similar. Median time to neutrophil recovery (Ͼ 0.5 ϫ 10 9 /L) after the start of first induction course was 27 days in the SD cytarabine arm v 25 days in the HD cytarabine arm. Median times to platelet recovery (Ͼ 100 ϫ 10 9 /L) were 29 days in the SD cytarabine arm and 27 days in the HD cytarabine arm.
After the consolidation course, grade 3 to 4 nonhematologic toxicities were similar in both arms. Median time to neutrophil recovery (Ͼ 0.5 ϫ 10 9 /L) was 22 days in both arms. Median time to platelet recovery in the SD v HD cytarabine arms was 20 v 22 days to reach 10 ϫ 10 9 /L platelets and 31 v 38 days to reach 100 ϫ 10 9 /L platelets.
DISCUSSION
This study demonstrates that at a median follow-up of 6 years in patients age 15 to 60 years with untreated AML, induction of remission using HD cytarabine in combination with daunorubicin and etoposide is associated with higher CR rate and survival chance than using the same regimen with SD cytarabine and without significant increase in toxicity. Survival advantage is significant for patients younger than age 46 years and for patients with secondary AML or with AML associated with very-bad-risk cytogenetic abnormalities or FLT3-ITD mutation. Our results differ from previously published randomized trials on HD cytarabine in the induction regimen.
14-17 Main differences are the number of induction cycles and the total doses of cytarabine administered before establishing treatment response and the number of patients per randomized arm (for details, see Appendix Table A1 , online only). We were impressed by the results of the Australian Leukemia Study Group, 14 which randomized remission induction with SD cytarabine and HD cytarabine, both combined with daunorubicin and etoposide, followed (in the case of CR) by two mild consolidation courses and 2 years of maintenance therapy. CR rates were 74% in the SD cytarabine arm and 71% in the HD cytarabine arm. Toxicity was significantly higher after HD cytarabine, and 18% of patients in the HD cytarabine arm died during induction compared with 11% in the SD cytarabine arm (P ϭ .09). For patients receiving HD cytarabine, significantly longer duration of remission, DFS, and survival for CR patients was reported. OS was not statistically different between the two arms. The relatively low number of patients included in the trial prevented further long-term analysis. We hypothesized that improvement in supportive care during induction together with availability of more intensive postremission strategies might decrease induction death and relapse rates. Furthermore, the inclusion of a larger number of patients would allow proper evaluation of a potential therapeutic advantage of HD cytarabine in induction therapy. On the basis of these arguments, we designed a large phase III study using both arms of the Australian protocol as well as the control arm of our most recent EORTC-GIMEMA AML-10 study.
In this study, stratification for age (15 to 45 and 46 to 60 years) at registration allowed profound statistical analysis in the two subgroups. In patients younger than age 46, the beneficial effect of HD cytarabine induction was consistently and significantly observed in terms of CR rate, EFS, and OS; in patients age 46 to 60 years, the positive effect of the increase in CR rate was counterbalanced by an increase in death in CR, translating into a small improvement in OS. Younger patients were expected to fare better with intensive chemotherapy and transplantation than older patients.
1,2 However, more intensive treatment and higher remission rates are usually not translated into longer survival. An age effect on survival was not reported by the Australian Leukemia Study Group. 15 Only the HOVON-SAKK (Cytarabine Dose for Acute Myeloid Leukemia) study 17 showed a trend in survival improvement in favor of HD cytarabine in patients younger than 36 years: 52% 5-year OS in the HD cytarabine arm and 42% in the intermediate-dose cytarabine arm (HR, 0.73, P ϭ .14). Although the HOVON-SAKK study did not show major differences between the intermediate-dose and HD cytarabine arms, it remains an unanswered question whether a comparison between SD cytarabine and .05
Multivariable analysis ‡ In contrast to the significantly increased toxicity observed in earlier trials, 14,15,17 except for significant conjunctivitis, we report that HD cytarabine, in the way it was administered as it was in our study, was not associated with higher toxicity including death during induction. As mentioned, this could reflect the inclusion of strict supportive guidelines in the treatment protocol. Longer duration of platelet recovery was documented only after the consolidation course. This finding has also been reported in the Australian Study, 14 the EORTC-GIMEMA AML-10 trial 2 and the HOVON-SAKK trial, 17 and may be as a result of increased stem-cell toxicity.
In the younger age group, donor versus no-donor analysis showed that availability of a donor improved the chances to remain alive in first CR equally in both randomized arms. In the older age group, a better antileukemic effect by allo-SCT may have been counterbalanced by a higher death rate as a result of transplantation complications. The number of transplantations using unrelated donor stem cells was too small to affect the results.
The planned subgroup analysis also showed clinically important superiority of HD cytarabine induction in patients with AML with very-bad-risk cytogenetic abnormalities, with FLT3-ITD mutation, and in patients with secondary AML. This is a particularly important finding since, thus far, only allo-SCT has been proven to favorably affect the dismal prognosis of these patients with bad-risk AML. 20 In conclusion, HD cytarabine in the induction treatment of patients age 15 to 45 years with AML significantly increased response rate and survival without significant increase in grade 3 to 4 toxicities. 
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